A German regional court granted Halozyme a preliminary injunction ordering Merck to halt distribution of subcutaneous Keytruda (pembrolizumab SC) in Germany, advancing a broader patent dispute between the companies. Halozyme said the ruling prevents Merck from offering the SC formulation pending resolution of patent claims tied to Halozyme’s hyaluronidase technology. Halozyme filed for the injunction after alleging infringement in the use of its dispersion-enhancing enzyme for subcutaneous delivery. Merck faces parallel litigation in multiple jurisdictions, and the German decision immediately affects market access for the SC formulation in that country. The case highlights the commercial and strategic importance of delivery-platform IP for high-value oncology antibodies; outcomes in Europe could influence licensing, formulation strategies and competitive dynamics for injectable versus subcutaneous presentations globally.